The Institute for Clinical and Economic Review (ICER) announced the release of a new white paper on alternative policies for pricing drugs and vaccines during a pandemic.
ICER is also set to host a three-part online series in which experts will discuss the advantages and disadvantages of different pricing methodologies.
“Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner,” ICER President Steven Pearson said in a statement. “One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.”
To read the white paper, click here.